Skip to content

Impact on the Time to Diagnosis of Serious Postoperative Complications by a Controlled Connected Medical Device

Impact on the Time to Diagnosis of Serious Post-operative Complications of Continuous, Individualised, Alert Monitoring of SpO2, Heart Rate and Respiratory Rate by a Controlled Connected Medical Device (SMART ANGEL Intra )

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05380310
Acronym
SMARTANGEL
Enrollment
2000
Registered
2022-05-18
Start date
2022-06-01
Completion date
2023-07-01
Last updated
2022-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Medical Device

Keywords

Connected Medical Device, Time to diagnosis, Post-operative mortality, SMART ANGEL intra-hospital system

Brief summary

Post-operative mortality in case of scheduled surgery is 3% in France (Lancet 2013) mainly due to cardiovascular or respiratory complications, by decompensation of pre-existing pathologies. Complications due to the medical practice are the third cause of morbidity (BMJ, 2016). More than half are preventable and are mainly observed in surgical patients. In conventional hospitalization, excluding intensive care, monitoring is done discontinuously for most of the patients, which does not allow early diagnosis of a vital cardiovascular or respiratory failure. Diagnosis and late treatment do not allow good recovery. The early identification of a vital failure by the continuous monitoring of three simple physiological parameters (SpO2, heart rate and respiratory rate) would allow faster management by the hospital staff and a reduction in immediate and possibly delayed postoperative mortality.

Detailed description

The challenge of this research is to transpose in an ordinary hospitalization unit the continuous monitoring of vital functions carried out in intensive care by the continuous measurement of simple parameters using the SMART ANGEL Intra-hospital System's (connected medical devices and alerts).

Interventions

DEVICEActive SMART ANGEL solution

Nurse intervention according to the alert level + traditional monitoring

DEVICEInactive SMART ANGEL solution

No alert + traditional monitoring + alert in case of imminent life threat

Sponsors

Evolucare Technologies
CollaboratorINDUSTRY
InES - Innovation Electronic Software
CollaboratorUNKNOWN
Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years * Patients receiving a scheduled non-ambulatory surgical or interventional procedure * Affiliation to a social security scheme, beneficiary or entitled person (excluding AME) * Patient's written consent or of the trusted person in case of physical incapacity

Exclusion criteria

* Inclusion in emergency situations * ASA1 patient (without associated pathology) * Patient with a multi-drug resistant germ in isolation * Known linguistic inability of the patient to understand the study * Known pregnancy or breastfeeding woman * Patients with implantable pacemakers, implantable defibrillators or neurostimulators. * Person under legal protection or unable to give consent * Person deprived of liberty by judicial or administrative decision

Design outcomes

Primary

MeasureTime frameDescription
Difference in response times for nursesbetween inclusion visit and day 30Difference in response times between the two groups as measured by the difference between the exact time of occurrence of the complication and the time of caregiver intervention.

Secondary

MeasureTime frameDescription
Mortality within 30 days of surgerybetween inclusion visit and day 30
Percentage of transfers to intensive care unitbetween inclusion visit and day 30
Length of staybetween inclusion visit and day 30
ICU length of staybetween inclusion visit and day 30
Rate of calls to the doctor on dutybetween inclusion visit and day 30
Percentage of re-hospitalization within 30 daysbetween inclusion visit and day 30
Mortality during hospitalisationbetween inclusion visit and day 30Within 30 days of the intervention
Percentage of patients managed at homebetween inclusion visit and day 30
False positive ratebetween inclusion visit and day 30Alert without complication for the patient
Incremental cost-effectiveness ratiobetween inclusion visit and day 30
Patient acceptabilitybetween inclusion visit and day 30Quantitative and qualitative assessment of the device's usability by the patient via Questionnaire and interview
Acceptability of care teamsbetween inclusion visit and day 30Questionnaire and interview
Percentage of hospitalisations in follow-up care and rehabilitation care unitsbetween inclusion visit and day 30

Countries

France

Contacts

Primary ContactJean-Louis MARTY, MD,PHD
jean.marty@aphp.fr01 49 81 43 45

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026